ENDRA Life Sciences: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
ENDRA Life Sciences (NASDAQ:NDRA) reported Q3 earnings with an EPS of $-0.4, beating estimates by 6.98% but with no change in revenue from the same period last year. The company's past earnings beat was followed by a share price drop the next day.
November 14, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ENDRA Life Sciences reported a better-than-expected Q3 EPS, but showed no revenue growth compared to last year. Previous earnings beat was followed by a decline in stock price.
While ENDRA Life Sciences exceeded EPS estimates, the lack of revenue growth and historical stock price drop following the last earnings beat suggest potential negative short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100